Ser266
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.6.0.2
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser266  -  PGC-1 alpha (human)

Site Information
SLPLtPEsPNDPKGs   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 448008

In vivo Characterization
Methods used to characterize site in vivo:
[32P] bio-synthetic labeling ( 4 ) , electrophoretic mobility shift ( 4 ) , mass spectrometry ( 1 , 2 ) , mutation of modification site ( 3 , 4 )
Disease tissue studied:
melanoma skin cancer ( 1 )
Relevant cell line - cell type - tissue:
'muscle, skeletal' ( 4 ) , BOSC ( 4 ) , C2C12 (myoblast) ( 4 ) , HeLa (cervical) ( 2 ) , hepatocyte ( 3 ) , WM239A (melanocyte) ( 1 )

Upstream Regulation
Putative in vivo kinases:
P38A (human) ( 4 )
Kinases, in vitro:
P38A (human) ( 4 )
Treatments:
SB202190 ( 4 )

Downstream Regulation
Effects of modification on PGC-1 alpha:
protein stabilization ( 4 )

References 

1

Stuart SA, et al. (2015) A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells. Mol Cell Proteomics 14, 1599-615
25850435   Curated Info

2

Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94
25159151   Curated Info

3

Wang W, Wong CW (2010) Statins enhance peroxisome proliferator-activated receptor gamma coactivator-1alpha activity to regulate energy metabolism. J Mol Med 88, 309-17
19915805   Curated Info

4

Puigserver P, et al. (2001) Cytokine stimulation of energy expenditure through p38 MAP kinase activation of PPARgamma coactivator-1. Mol Cell 8, 971-82
11741533   Curated Info